* Startseite     * Über...     * Archiv     * Gästebuch     * Kontakt     * Abonnieren

* Letztes Feedback

PWRM, DCAI, DrStockPick.com Stock Report! Power 3 Medical Products Inc. and Dialysis Corporation of

Dr Stock Pick HOT News & Alerts!



FREE Daily Stock Alerts From DrStockPick.com



Wednesday April 14, 2010

DrStockPick.com Stock Report!


PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM?s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer?s, and Parkinson?s diseases, breast cancer, and drug resistance.

** PWRM reported that 4 abstracts covering results from clinical validation trials of the NuroPro(R) AD test for Alzheimer?s disease were submitted to the 2010 annual meeting of the International Congress of Alzheimer?s Disease, taking place July 2010. The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer?s disease from ?normal? individuals and patients with other neurological disorders. The test, developed by PWRM, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer?s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.

The four studies present the capabilities of NuroPro for accurate diagnosis, targeted therapy and drug response monitoring. They involve a total of 154 Alzheimer?s disease and 91 Parkinson?s disease patients, 210 age-matched normal and 173 disease control individuals. The abstracts report the combined results from the clinical validation trials of the NuroPro(R) AD and NuroPro PD tests, conducted by the PWRM scientific team, led by medical director Lourdes R. Bosquez, MD and chief scientific officer, Ira L. Goldknopf, Ph.D., in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute, Sun City, Arizona, Katerina Markopoulou, M.D., Assistant Professor of Neurology at the University of Thessaly, Larissa Greece, along with previous studies PWRM conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology, Baylor College of Medicine, Houston TX. Dr. Appel is now Co-Director of the Methodist Neurological Research Institute, Houston, TX, and continues to be chairman of the scientific advisory board of Power3.

Furthermore, PWRM has signed a definitive agreement to acquire all of the stock of StemTroniX Inc. PWRM plans to effectuate the acquisition of StemTroniX by merging a wholly owned subsidiary of the Company with and into StemTroniX. StemTroniX will remain as the surviving company in the merger and will become a wholly owned subsidiary of PWRM. The acquisition of StemTroniX is expected to be completed in April 2010.

More about PWRM at www.Power3Medical.com


DCAI, Dialysis Corporation of America, Inc.

DCAI owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in the those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.

U.S. Renal Care, Inc. ("USRC"), a privately-held leading provider of outpatient dialysis services, and DCAI, a leading provider of outpatient kidney dialysis centers, announced today that they have entered into a definitive merger agreement for USRC to acquire DCA.

Under the terms of the agreement, USRC, through a subsidiary, will commence a tender offer for all of the outstanding common shares of DCAI for $11.25 per share in cash, followed by a merger to acquire all remaining outstanding DCAI's shares at the same cash price paid in the tender offer. The offer price represents a premium of approximately 72 percent over yesterday's closing stock price. The transaction is valued at approximately $112 million.

Upon the closing of the transaction, USRC will provide dialysis services to a base of approximately 5,500 patients through 84 outpatient dialysis facilities across nine states, more than 12 home dialysis programs, and 24 dialysis programs within acute and specialty hospital facilities.

More about DCAI at www.dialysiscorporation.com.


Keep a close eye on PWRM and DCAI, do your homework, and like always BE READY for the ACTION!









crown equity holdingscrown trading systemscrwe news wirecrwe newsbest otccrwe financecrwe pickscrwe selectcrwe wallstreetdouble in stocksdr stock pickpenny to buckpenny omegastock hot tipsstock-prhot otcbest stock reportstock eggpenny stock chaserxplosive stockswallst grandnebula stockspower penny playsstock richstock marketing inc.princeton reasearchmomentum traders networkbest damn penny stockstitan stocksshakerz and moverzinformation solutions grouppenny stock farmnano cap gemspen stoxstock front runnersstock starsswiss financial reportlogo formagits all bullwakabayashi fund best of otcstock explodercohen researchpenny governance






Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).






Dr. Stock Pick is a seasoned equity trader and financial investor. He?s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He?s syndicated on over 1400 websites www.crwenews.com, www.stock-ir.com, www.PennyOmega.com, www.PennyToBuck.com, www.BestOTC.com, www.stock-pr.com, www.crwenewswire.com, www.CRWEFinance.com, www.PennyGovernance.com, giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com



Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you?re looking for a multi display computer to enhance your trading then you?ll want to visit www.crowntradingsystems.com
14.4.10 18:16


bisher 0 Kommentar(e)     TrackBack-URL

E-Mail bei weiteren Kommentaren
Informationen speichern (Cookie)

Die Datenschuterklärung und die AGB habe ich gelesen, verstanden und akzeptiere sie. (Pflicht Angabe)

 Smileys einfügen

Verantwortlich für die Inhalte ist der Autor. Dein kostenloses Blog bei myblog.de! Datenschutzerklärung